Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2016
Reporting Period: Quarter ended June 30, 2016
This filing serves as a notification that the Company issued a press release on August 8, 2016, announcing its financial results for the quarter ended June 30, 2016. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. It only confirms the announcement of results for the quarter ended June 30, 2016.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document explicitly states that the information in the press release (Exhibit 99.1) is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 8, 2016) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the Company's product pipeline and clinical trial status mentioned in the press release.
- Confirm the Company's liquidity position and runway based on the cash balance reported in the full press release.
- Check for any updated guidance or forward-looking statements in the press release that are not included in this 8-K cover sheet.